Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

Similar articles for PubMed (Select 20419121)

1.

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA.

PLoS One. 2010 Apr 15;5(4):e10186. doi: 10.1371/journal.pone.0010186.

2.

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.

Walsby EJ, Coles SJ, Knapper S, Burnett AK.

Haematologica. 2011 Mar;96(3):393-9. doi: 10.3324/haematol.2010.032680. Epub 2010 Dec 6.

3.

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.

Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA.

Oncotarget. 2010 Nov;1(7):606-19.

4.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
5.

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC.

Clin Cancer Res. 2010 Apr 1;16(7):2167-75. doi: 10.1158/1078-0432.CCR-09-2236. Epub 2010 Mar 16.

6.

Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.

Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC.

J Thorac Oncol. 2011 Feb;6(2):384-6. doi: 10.1097/JTO.0b013e318200e509.

PMID:
21252718
7.

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.

Scatena CD, Kumer JL, Arbitrario JP, Howlett AR, Hawtin RE, Fox JA, Silverman JA.

Cancer Chemother Pharmacol. 2010 Oct;66(5):881-8. doi: 10.1007/s00280-009-1234-z. Epub 2010 Jan 8.

8.

Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.

Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N.

J Biol Chem. 1991 Aug 5;266(22):14585-92.

9.

Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.

Smith PJ, Sou├Ęs S, Gottlieb T, Falk SJ, Watson JV, Osborne RJ, Bleehen NM.

Br J Cancer. 1994 Nov;70(5):914-21.

10.

Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.

Drummond CJ, Finlay GJ, Broome L, Marshall ES, Richardson E, Baguley BC.

Invest New Drugs. 2011 Oct;29(5):1102-10. doi: 10.1007/s10637-010-9473-8. Epub 2010 Jun 22.

PMID:
20567995
11.

Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.

Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.

Clin Cancer Res. 2000 Apr;6(4):1488-97.

12.

Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.

Marx G, Zhou H, Graves DE, Osheroff N.

Biochemistry. 1997 Dec 16;36(50):15884-91.

PMID:
9398321
13.

Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.

Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M, et al.

Biochemistry. 1991 Apr 23;30(16):4048-55.

PMID:
1850298
15.

Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.

Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL.

Mol Cancer Ther. 2006 Jun;5(6):1405-14.

16.
17.
18.

[Poisons of DNA topoisomerases I and II].

Charcosset JY, Soues S, Laval F.

Bull Cancer. 1993 Nov;80(11):923-54. Review. French.

PMID:
8081034
19.

Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.

Kizaki H, Onishi Y.

Adv Enzyme Regul. 1997;37:403-23.

PMID:
9381984
20.

Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.

Anderson VE, Osheroff N.

Curr Pharm Des. 2001 Mar;7(5):337-53. Review.

PMID:
11254893
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk